On April 22, 2026, Telomir Pharmaceuticals, Inc. completed the acquisition of TELI Pharmaceuticals, Inc. by issuing 34,389,710 shares of common stock, consolidating global rights to Telomir-1 under one corporate structure. The merger was previously approved by shareholders on March 23, 2026, enhancing Telomir's control over its key product development.